The purpose of this email is to inform you of two North Carolina Immunization Program (NCIP) ordering updates that may affect your practice. Please review the information below and reach out with any questions.
Topics Related to Immunization
The purpose of this memo is to provide important details regarding the upcoming holiday vaccine shipping schedule for the Vaccines for Children (VFC) and the 317 Vaccines for Adults (317 VFA) programs.
All public, private, and religious colleges and universities in North Carolina are required to submit an immunization report annually to the North Carolina Department of Health and Human Services (G.S. 130A-155.1(c)). This report ensures all students enrolled in your institution are protected against vaccine-preventable diseases and determines the number of students who meet state immunization requirements.
On Oct. 6, 2025, the Acting CDC Director approved the Advisory Committee on Immunization Practices (ACIP) COVID-19 vaccine recommendations. The CDC has updated its adult and child immunization schedules to apply individual-based decision-making to COVID-19 vaccination for 6 months and older, after consultation with a healthcare provider.
North Carolina Vaccines for Children (VFC) providers can now order the pentavalent meningococcal (A,B,C,W, and Y) vaccine, PENMENVY™ (NDC 58160-757-15) via NCIR for administration to their VFC-eligible adolescents (ages 10 through 18 years).
The purpose of this memo is to provide North Carolina Immunization Program (NCIP) providers with the latest information on the 2025-2026 COVID-19 vaccine. Please take time to carefully review this memo in full. COVID-19 vaccines for VFC-eligible patients are now available to order through NCIR.
The purpose of this memo is to notify childcare operators/Head Start directors and Pre-K classrooms of the 2025 annual immunization reporting requirements.
This email is to inform you that the North Carolina Immunization Program (NCIP) has opened applications for birthing hospitals interested in participating in the replacement model for birth dose Hepatitis B and RSV.
The purpose of this email is to inform VFC-enrolled providers that the RSV monoclonal antibody product clesrovimab (trade name ENFLONSIA™ manufactured by Merck) is now available for ordering. VFC doses will begin shipping after Oct. 2, 2025.
The purpose of this memo is to remind local health department (LHD) staff about the upcoming 2025 Annual Immunization Assessment. This assessment will review NCIR records of children, 24 through 35 months old, who are labeled "active" in NCIR under the LHD site, as well as all children that live in the county.